Dersimelagon by Tanabe Pharma America — Product Research | aVenture Research
Dersimelagon, also designated MT-7117, is an investigational oral selective melanocortin-1 receptor agonist developed to reduce phototoxicity in adult and adolescent patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The Phase 3 INSPIRE program met its primary endpoint, and the candidate holds U.S. FDA Fast Track and Orphan Drug designations.
Tanabe Pharma America submitted the U.S. new drug application, which was accepted for priority review, while global rights to the asset were transferred to LEO Pharma in 2026; Tanabe retains responsibility for the U.S. regulatory outcome.
SCENESSE (afamelanotide) is CLINUVEL's approved subcutaneous melanocortin-1 receptor agonist implant that increases pain-free light exposure in adults with erythropoietic protoporphyria.
SCENESSE (afamelanotide) is CLINUVEL's approved subcutaneous melanocortin-1 receptor agonist implant that increases pain-free light exposure in adults with erythropoietic protoporphyria.